excerpt: "We are currently amassing the safety and pharmacologic data required for filing an IND (investigational new drug) with the FDA as a prelude to a first-in-human clinical trial. Cancers that express ID in resting stem cells have high relapse rates and poor prognoses. These will be the first cancers we will be treating with our new oral formulations."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.